BioNTech SE announced that the FDA placed a partial clinical hold on their Phase 3 trial, PRESERVE-003, for BNT316/ONC-392 due to varying results among non-small cell lung cancer patients; the hold affects new patient enrollments but not current participants as of October 18, 2024.